Gujarat Terce Laboratories Ltd Valuation Shifts to Very Attractive Amid Sector Challenges

Valuation Metrics Signal Renewed Appeal

As of 2 June 2026, Gujarat Terce Laboratories Ltd trades at a price of ₹35.06, marginally up 0.86% from the previous close of ₹34.76. The stock’s 52-week range spans from ₹29.00 to ₹60.01, indicating a substantial correction from its highs. The company’s micro-cap status and a Mojo Score of 37.0, with a Mojo Grade upgraded from Strong Sell to Sell on 1 June 2026, reflect a cautious but improving outlook.

Most notably, the company’s price-to-earnings (P/E) ratio stands at 11.17, a stark contrast to its peers such as Bliss GVS Pharma and Kwality Pharma, which trade at P/E multiples exceeding 30. This valuation places Gujarat Terce Laboratories in the “very attractive” category, signalling that the stock is trading at a significant discount relative to earnings potential. The price-to-book value (P/BV) ratio of 2.81 further supports this view, suggesting the market values the company at less than three times its net asset value, a reasonable level for a pharmaceutical firm with strong returns on capital.

Enterprise value to EBITDA (EV/EBITDA) at 6.49 and EV to EBIT at 7.33 also underscore the stock’s relative cheapness compared to sector averages, where many peers command multiples well above 15. The company’s PEG ratio of 0.03 is exceptionally low, indicating that the stock’s price is not only inexpensive relative to current earnings but also undervalued when factoring in growth prospects.

Robust Return Ratios Bolster Valuation Case

Gujarat Terce Laboratories’ return on capital employed (ROCE) is an impressive 48.83%, while return on equity (ROE) stands at 25.13%. These figures indicate efficient capital utilisation and strong profitability, which justify the company’s valuation despite recent price weakness. Such high returns are rare in the micro-cap pharmaceutical space and provide a cushion against sector volatility.

Comparatively, many peers with higher valuations do not demonstrate equivalent capital efficiency, which raises questions about their premium multiples. For instance, companies like NGL Fine Chem and Hester Bios command P/E ratios above 30 but do not match Gujarat Terce Laboratories’ ROCE and ROE levels, suggesting the latter may be undervalued on a quality-adjusted basis.

Price Performance and Market Context

Examining the stock’s price performance relative to the Sensex reveals a mixed picture. Over the past week, Gujarat Terce Laboratories declined by 0.37%, outperforming the Sensex’s 2.90% drop. However, over the one-month and year-to-date periods, the stock has underperformed, falling 6.78% and 19.40% respectively, compared to the Sensex’s declines of 3.44% and 12.85%. The one-year return is particularly weak at -35.49%, versus the Sensex’s -8.82%, reflecting sector headwinds and company-specific challenges.

Despite this, the longer-term returns are compelling. Over three, five, and ten years, Gujarat Terce Laboratories has delivered cumulative returns of 64.76%, 289.12%, and 382.26% respectively, substantially outperforming the Sensex’s 18.96%, 43.00%, and 178.01% returns. This track record of long-term wealth creation supports the argument that the current valuation reset may offer a buying opportunity for patient investors.

Peer Comparison Highlights Valuation Disparity

Within the Pharmaceuticals & Biotechnology sector, Gujarat Terce Laboratories stands out for its valuation attractiveness. While companies such as Bliss GVS Pharma, Kwality Pharma, and Jagsonpal Pharma are rated as “Very Expensive” with P/E ratios above 29 and EV/EBITDA multiples exceeding 20, Gujarat Terce Labs trades at a fraction of these levels. Venus Remedies and TTK Healthcare are rated “Attractive” but still carry higher multiples than Gujarat Terce Labs.

This divergence suggests that the market may be overlooking Gujarat Terce Laboratories’ strong fundamentals and capital efficiency. The company’s micro-cap status and lower liquidity could be factors contributing to this discount, but the valuation gap presents a potential entry point for investors seeking value in the pharmaceutical space.

Risks and Considerations

Despite the attractive valuation, investors should be mindful of the company’s recent underperformance and the broader sector challenges, including regulatory pressures, pricing constraints, and competitive intensity. The absence of a dividend yield also means returns are reliant on capital appreciation. Furthermore, the Mojo Grade of Sell, albeit an upgrade from Strong Sell, indicates caution remains warranted.

Investors should weigh these risks against the company’s strong return ratios and valuation discount, considering their investment horizon and risk tolerance before committing capital.

Conclusion: Valuation Reset Offers Potential Opportunity

Gujarat Terce Laboratories Ltd’s shift from a very expensive to a very attractive valuation grade marks a notable development in the Pharmaceuticals & Biotechnology micro-cap segment. With a P/E ratio of 11.17, EV/EBITDA of 6.49, and a PEG ratio near zero, the stock is priced for value relative to its peers and historical multiples.

Strong return metrics such as a 48.83% ROCE and 25.13% ROE reinforce the company’s operational quality, while long-term returns have significantly outpaced the broader market. However, recent price underperformance and sector risks warrant a measured approach.

For investors seeking exposure to a fundamentally sound pharmaceutical micro-cap at an attractive valuation, Gujarat Terce Laboratories presents a compelling case to consider within a diversified portfolio.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →